1.00 / AMA PRA Category 1 Credit(s)TM 1.00 / CE for Nurses (includes 1.00 pharmacology credit)
Provided by Office of Continuing Medical Education, Boston University School of Medicine (BUSM)
Endorsed by the AGA Institute
This educational activity is supported by an independent medical educational grant from Pfizer Inc.
Inflammatory bowel disease (IBD) affects a substantial number of individuals and though significant advances have been made in its treatment, many patients still do not achieve remission. As research reveals more insight into the pathophysiology of IBD, novel therapeutic targets are being identified that lead to the development of new therapeutic agents. These unique treatment options will give patients who have not been able to achieve treatment goals more options and a greater chance for success. As more information becomes available about IBD, gastroenterologists and other clinicians must be knowledgeable and fully prepared to use this information in their practice and employ new agents as they become available. Utilizing a panel of expert faculty and featuring video vignettes of actual patients, the objective of this web-based activity is to provide clinicians with a better understanding of the latest data regarding evolving treatment goals in IBD and about the adoption of an individualized treatment approach to the selection, initiation, and tailoring of biologic therapies for achieving and sustaining remission of IBD.
This activity is intended for gastroenterologists, nurse practitioners, nurses and physician assistants who work with gastroenterology practices and/or treat patients with IBD.
At the conclusion of this activity, participants will be able to (or better able to):
Assess patients who are unable to achieve remission to determine potential causes of treatment failure and modify treatment in an appropriate manner
Analyze the underlying mechanisms and disease progression of IBD and how it relates to current treatment strategies and the need for novel therapies
Discuss the safety and efficacy data for new and emerging therapeutic options for IBD, including unique mechanisms of action and potential place in therapy
Conflict Of Interest Disclosure Policy
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Francis A. Farraye, MD, MSc Course Director Clinical Director in the Section of Gastroenterology Director of the Inflammatory Bowel Disease Center Boston Medical Center Professor of Medicine Boston University School of Medicine Boston, MA
Dr. Farraye discloses that he is a consultant for Abbvie, Braintree, Celgene, Ferring, Janssen, Merck, Pfizer, Puma, and Takeda. He also receives grant/research support from Prometheus, is a stockholder for Cellceutix, and is on the data safety management board for Mesoblast and Protagonist.
Dr. Moss discloses that he is a consultant for Janseen, Seres, and Theravance.
Accredited Provider Disclosure
Michael Burk, Senior Program Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has nothing to disclose relevant to commercial support.
Patti-Ann Collins, Lead Nurse Planner for Boston University School of Medicine’s Office of Continuing Medical Education, has nothing to disclose relevant to commercial support.
Dana Frazier, Program and Grant Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has nothing to disclose relevant to commercial support.
Beth-Ann Norton, Nursing Course Advisor for Boston University School of Medicine’s Office of Continuing Medical Education, discloses that she formerly served as a consultant for Janssen.
Laura Stinson, consultant medical editor for Boston University School of Medicine’s Office of Continuing Medical Education, has nothing to disclose relevant to commercial support.
AMA PRA Category 1 Credit(s)TM
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.00 CNE Contact Hour, all of which is eligible for pharmacology credit.
Disclosure of Unlabeled Use
The faculty members do plan on discussing the unlabeled/investigational use of azathioprine, mongerson, ozaminod, and tofactinib.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For any CME or CNE accreditation questions, please contact BUSM’s CME office at 617-638-4605 or email@example.com.